RGCC

RGCC (Research Genetic Cancer Centre) is a global biotechnology organization specializing in personalized oncology and precision medicine. Founded in 2004, the company has developed a comprehensive suite of liquid biopsy tests designed to detect, analyze, and monitor circulating tumor cells (CTCs) and cancer stem cells (CSCs). Their flagship services, such as Onconomics and Oncotrace, provide detailed genetic profiling and chemosensitivity analysis to help clinicians identify the most effective treatments for individual patients. Beyond diagnostics, RGCC offers personalized therapeutic interventions, including Supportive Oligonucleotide Technique (SOT) and autologous cell-based therapies. The company operates a state-of-the-art laboratory in Greece and maintains a presence in over 40 countries through a network of partner clinics. RGCC's mission is to empower patients and physicians with actionable data to improve cancer outcomes through tailored medical strategies.